Ironwood Pharmaceuticals (IRWD) Rating Lowered to Hold at BidaskClub

Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Several other equities research analysts have also recently issued reports on IRWD. Cowen set a $20.00 price objective on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 21st. Mizuho restated a “buy” rating and set a $20.00 price objective (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Credit Suisse Group initiated coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Ironwood Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $17.88.

Shares of Ironwood Pharmaceuticals (IRWD) traded up $0.40 during trading hours on Thursday, reaching $15.49. The company’s stock had a trading volume of 528,145 shares, compared to its average volume of 1,244,725. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals has a 52-week low of $13.43 and a 52-week high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The firm had revenue of $86.80 million for the quarter, compared to analysts’ expectations of $73.59 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. Ironwood Pharmaceuticals’s quarterly revenue was up 31.3% on a year-over-year basis. equities research analysts forecast that Ironwood Pharmaceuticals will post -1.12 earnings per share for the current year.

In related news, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now owns 4,696,917 shares in the company, valued at $71,017,385.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 115,769 shares of company stock worth $1,752,491 in the last quarter. 7.63% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. boosted its holdings in Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 648 shares during the last quarter. Aperio Group LLC boosted its holdings in Ironwood Pharmaceuticals by 11.9% in the second quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock valued at $249,000 after acquiring an additional 1,410 shares during the last quarter. Amalgamated Bank boosted its holdings in Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 1,421 shares during the last quarter. Virtu KCG Holdings LLC boosted its holdings in Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 1,470 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Ironwood Pharmaceuticals by 5.0% in the second quarter. Legal & General Group Plc now owns 47,773 shares of the biotechnology company’s stock valued at $900,000 after acquiring an additional 2,265 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/09/ironwood-pharmaceuticals-irwd-rating-lowered-to-hold-at-bidaskclub.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply